Qiagen To Market HLA Typing Technology from Genome Diagnostics

Oct 10, 2006

NEW YORK (GenomeWeb News) – Qiagen secured commercial rights to sell reagents and software for Genome Diagnostics' sequencing based typing technology, Genome Diagnostics said yesterday.

The Dutch company has developed a proprietary strategy for typing human leukocyte antigen genes. Qiagen will have global distribution rights to the technology as of January 2007.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Yep, Couple of Concerns There

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

Passing on Trauma, Maybe

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

Told to Pause

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

This Week in PNAS

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.

Main menu